Kyle Blankenship, Senior Editor, Endpoint News

January 13, 2021

In the massive immunology market, some of pharma’s biggest players are looking for novel pathways to treat disease areas already packed with big-name drugs. Now, with an immunology blockbuster of its own in Otezla, Amgen is ponying up to partner with a Michigan discovery outfit looking to target dendritic cells to churn up immune tolerance.

Amgen will pay $240 million in upfront cash and milestone payments for molecules targeting autoimmune conditions from Ann Arbor, MI-based Evoq Therapeutics, a spinoff of research from the University of Michigan, the biotech said Wednesday.

Read the full article at Endpoint News